[Form 4] Avanos Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Gary Blackford, a director of Avanos Medical, Inc. (AVNS), reported purchases of a total of 60,000 shares on 08/13/2025 in two grouped transactions: 20,000 shares acquired at a weighted-average price of $10.975 and 40,000 shares acquired at a weighted-average price of $10.995.

Following these transactions the filing shows 91,593 shares beneficially owned directly and 40,000 shares held indirectly in trusts for immediate family members (the reporting person is co-trustee and disclaims beneficial ownership except to the extent of pecuniary interest). The Form 4 was signed by an attorney-in-fact on 08/15/2025.

Insights

Securities Analyst

TL;DR: Director acquired 60,000 shares in two purchases at roughly $10.98, increasing both direct and indirect holdings.

The Form 4 documents two purchase transactions on 08/13/2025 totaling 60,000 common shares at weighted-average prices of $10.975 and $10.995. After the transactions, the reporting line shows 91,593 shares held directly and 40,000 held indirectly in family trusts. The filing includes standard footnotes disclosing price ranges for the multiple trades and a disclaimer of beneficial ownership for the trust-held shares. This disclosure is routine insider reporting required by Section 16 and provides clear, transaction-level transparency.

Corporate Governance Expert

TL;DR: Director purchases documented; trust holdings disclosed with co-trustee status and disclaimer of beneficial ownership.

The Form 4 properly reports purchases aggregated as weighted-average prices and supplies explanatory footnotes about trade price ranges and trust arrangements. The reporting person is identified as a director and co-trustee for shares held in trusts for immediate family members, with a disclaimer limiting beneficial ownership to pecuniary interest. The form appears complete for the transactions reported and is signed by an attorney-in-fact on behalf of the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BLACKFORD GARY

(Last) (First) (Middle)

5405 WINDWARD PARKWAY

(Street)

ALPHARETTA GA 30004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		P		20,000	A	$10.975(1)	91,593	D
Common Stock	08/13/2025		P		40,000	A	$10.995(2)	40,000	I	Shares held in trust.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.94 to $11.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.98 to $11.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. These shares are held in trusts for the benefit of certain immediate family members of the Reporting Person. The Reporting Person is co-trustee of such trusts. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Mojirade James, as attorney-in-fact for Gary D. Blackford	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Gary Blackford report for AVNS on Form 4?

He reported two purchases on 08/13/2025 totaling 60,000 common shares at weighted-average prices of $10.975 and $10.995.

How many Avanos (AVNS) shares does the filing show Mr. Blackford owns after the transactions?

The filing shows 91,593 shares beneficially owned directly and 40,000 shares held indirectly in trusts.

Are the trust-held shares reported by the Avanos director considered beneficially owned?

The filing states the shares are held in trusts for immediate family members, the reporting person is co-trustee, and he disclaims beneficial ownership except to the extent of pecuniary interest.

When was the Form 4 signature dated for the Avanos insider filing?

The signature block shows the form was signed by an attorney-in-fact on 08/15/2025.

Do the reported prices represent single trades or ranges?

Each reported price is a weighted-average; footnotes disclose the underlying trade price ranges ($10.94–$11.01 and $10.98–$11.04) and offer to provide detailed allocations on request.